Sutro Biopharma Inc. (NASDAQ: STRO) presented preclinical data on its antibody drug conjugate programs at the American Association for Cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE